Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTRLW2X)

• DTT Name: Fibroblast growth factor receptor 1 (FGFR1) DTT Info
• Gene Name: FGFR1

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[1]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[2]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[3]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[4]

12 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[5]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[7]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[8]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[9]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
FGF-1	DMXMC8I	Coronary heart disease	BA80.Z	Phase 2	[11]
FP-1039	DMUAXS5	Endometrial cancer	2C76	Phase 2	[12]
MK-3655	DMM5SVL	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[13]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[14]
KW-2449	DMFO7RP	Acute myeloid leukaemia	2A60	Phase 1	[15]
NGM313	DMYNSRH	Type-2 diabetes	5A11	Phase 1	[16]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-695735	DMQG39T	Solid tumour/cancer	2A00-2F9Z	Preclinical	[17]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[18]

19 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	DM0CSH8	Discovery agent	N.A.	Investigative	[19]
3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine	DMU53NZ	Discovery agent	N.A.	Investigative	[20]
3-Benzimidazol-2-ylhydroquinolin-2-one	DMQXJA1	Discovery agent	N.A.	Investigative	[21]
AAL-993	DM35RFH	Discovery agent	N.A.	Investigative	[4]
ACTB-1003	DMPHSU8	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
Anti-FGFR1 mab program	DMP5VZQ	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
HKI-9924129	DM5LR2B	Gram-positive bacterial infection	1B74-1G40	Investigative	[22]
NP-506	DMVPIF8	Discovery agent	N.A.	Investigative	[23]
PD-0166326	DMD2CG9	Discovery agent	N.A.	Investigative	[22]
PD-0173952	DMSCQ9U	Discovery agent	N.A.	Investigative	[22]
PD-0173955	DMOZEW9	Discovery agent	N.A.	Investigative	[22]
PD-0173956	DM8RW92	Discovery agent	N.A.	Investigative	[22]
PD-0173958	DMZQ8YV	Discovery agent	N.A.	Investigative	[22]
PD-0179483	DMKO8LE	Discovery agent	N.A.	Investigative	[22]
PMID22765894C8h	DMH5RFU	Discovery agent	N.A.	Investigative	[24]
PMID24900538C2c	DM5PATM	Discovery agent	N.A.	Investigative	[25]
PMID26080733C7r	DM8D6ZL	Discovery agent	N.A.	Investigative	[26]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[27]
SAR-106881	DM2J0UN	Peripheral arterial disease	BD4Z	Investigative	[5]

References

• [1] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [4] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [6] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [7] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [8] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70.
• [12] FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927.
• [13] Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Des Devel Ther. 2021 Sep 22;15:3997-4009.
• [14] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [15] KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
• [18] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
• [19] Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
• [20] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [21] Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92.
• [22] Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
• [23] 5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases. Bioorg Med Chem Lett. 2009 Feb 1;19(3):745-50.
• [24] The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
• [25] Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
• [26] Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold. Org Biomol Chem. 2015 Jul 28;13(28):7643-54.
• [27] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.